March 2015 in “The Journal of Urology” Finasteride reduces PSA levels by around 40-50% in BPH patients.
12 citations
,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
March 2013 in “The Journal of Urology” Non-daily Dutasteride is more cost-effective and has lower cancer incidence than daily treatment.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
July 2014 in “Urologia Journal” 5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.